Evaluation of short-term use of N-acetylcysteine as a strategy for prevention of anthracycline-induced cardiomyopathy: EPOCH trial - A prospective randomized study

Korean Circulation Journal

Volumn 43, Issue 3, 2013, Pages 174-181

  Jo, Sang Ho ^a   Kim, Lee Su ^a   Kim, Sung Ai ^a   Kim, Hyun Sook ^a   Han, Sang Jin ^a   Park, Woo Jung ^a   Choi, Young Jin ^b  

^a Hallym University   (South Korea)

^b Sejong General Hospital   (South Korea)

Author keywords

Acetylcysteine; Anthracyclines; Cardiomyopathies

Indexed keywords

ACETYLCYSTEINE; ANTHRACYCLINE; DOXORUBICIN; EPIRUBICIN; HEART ENZYME;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY;

EID: 84876722465     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2013.43.3.174     Document Type: Article

References (27)

1. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864-71. (Pubitemid 41095177)
2. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-54. (Pubitemid 38737923)
3. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62:873-9. (Pubitemid 8377881)
4. Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents 2003;3:151-71. (Pubitemid 36221735)
5. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330-52.
6. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management Circulation 2004;109:3122-31.
7. Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, Wojnowski L. Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med 2007;42:466-73. (Pubitemid 46162116)
8. Spallarossa P, Altieri P, Garibaldi S, et al. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 2006;69:736-45. (Pubitemid 43139736)
9. Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 1981;68:1053-64. (Pubitemid 11023534)
10. Rosenthal DS, Braunwald E. Cardiac effects of radiation therapy and chemotherapy. In: Braunwald E editor. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders Co.;2001. p.1746-51.
11. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302. (Pubitemid 30213944)
12. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-81. (Pubitemid 44901520)
13. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
14. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
15. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79. (Pubitemid 36605157)
16. Figueredo VM. Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart. Am J Med 2011;124:480-8.
17. Hong HJ, Liu JC, Chen PY, Chen JJ, Chan P, Cheng TH. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway. Int J Cardiol 2012;157:174-9.
18. Chao HH, Liu JC, Hong HJ, Lin JW, Chen CH, Cheng TH. L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes. Int J Cardiol 2011;146:145-52.
19. Li L, Takemura G, Li Y, et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006;113:535-43.
20. Li K, Sung RY, Huang WZ, et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006;113:2211-20.
21. Neilan TG, Jassal DS, Scully MF, et al. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. Eur Heart J 2006;27:1251-6.
22. Kalay N, Basar E, Ozdogru I, et al. Protective effects of Carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62. (Pubitemid 44855419)
23. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4. (Pubitemid 30489215)
24. Feola M, Garrone O, Occelli M, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011;148:194-8.
25. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007;12:131-42. (Pubitemid 46916959)
26. Urbanova D, Urban L, Danova K, Simkova I. Natriuretic peptides: biochemical markers of anthracycline cardiac toxicity? Oncol Res 2008;17:51-8. (Pubitemid 351796811)
27. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.